# Proto Labs Inc: financial statements, quarterly PRLB · NYSE · CIK 1443669 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prlb.md) · [Financials](/companies/prlb/financials.md) · [Filings](/companies/prlb/filings.md) · [Insiders](/companies/prlb/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prlb/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [131](/filings/0001628280-24-046196.md) | [125 d](/filings/0001443669-26-000010.md) | [128](/filings/0001628280-25-021822.md) | [126](/filings/0001628280-25-037024.md) | [126](/filings/0001443669-25-000013.md) | [122 d](/filings/0001443669-26-000010.md) | [126](/filings/0001443669-26-000025.md) | [135](/filings/0001443669-26-000035.md) | [135](/filings/0001443669-25-000013.md) | [136 d](/filings/0001443669-26-000010.md) | [139](/filings/0001443669-26-000025.md) | [149](/filings/0001443669-26-000035.md) | | Cost of revenue | $m | [71.4](/filings/0001628280-24-046196.md) | [69.2 d](/filings/0001443669-26-000010.md) | [70.4](/filings/0001628280-25-021822.md) | [69.1](/filings/0001628280-25-037024.md) | [68.4](/filings/0001443669-25-000013.md) | [69.8 d](/filings/0001443669-26-000010.md) | [70.5](/filings/0001443669-26-000025.md) | [75.3](/filings/0001443669-26-000035.md) | [74.1](/filings/0001443669-25-000013.md) | [76.1 d](/filings/0001443669-26-000010.md) | [75.7](/filings/0001443669-26-000025.md) | [80.0](/filings/0001443669-26-000035.md) | | Gross profit | $m | [59.3](/filings/0001628280-24-046196.md) | [55.8 d](/filings/0001443669-26-000010.md) | [57.5](/filings/0001628280-25-021822.md) | [56.5](/filings/0001628280-25-037024.md) | [57.2](/filings/0001443669-25-000013.md) | [52.0 d](/filings/0001443669-26-000010.md) | [55.7](/filings/0001443669-26-000025.md) | [59.8](/filings/0001443669-26-000035.md) | [61.3](/filings/0001443669-25-000013.md) | [60.4 d](/filings/0001443669-26-000010.md) | [63.6](/filings/0001443669-26-000025.md) | [69.3](/filings/0001443669-26-000035.md) | | Research and development | $m | [10.1](/filings/0001628280-24-046196.md) | [9.5 d](/filings/0001443669-26-000010.md) | [11.2](/filings/0001628280-25-021822.md) | [10.7](/filings/0001628280-25-037024.md) | [9.8](/filings/0001443669-25-000013.md) | [9.7 d](/filings/0001443669-26-000010.md) | [10.6](/filings/0001443669-26-000025.md) | [11.2](/filings/0001443669-26-000035.md) | [10.7](/filings/0001443669-25-000013.md) | [10.3 d](/filings/0001443669-26-000010.md) | [10.5](/filings/0001443669-26-000025.md) | [10.8](/filings/0001443669-26-000035.md) | | Operating income | $m | [10.4](/filings/0001628280-24-046196.md) | [8.4 d](/filings/0001443669-26-000010.md) | [6.8](/filings/0001628280-25-021822.md) | [6.0](/filings/0001628280-25-037024.md) | [8.6](/filings/0001443669-25-000013.md) | [(1.5) d](/filings/0001443669-26-000010.md) | [4.5](/filings/0001443669-26-000025.md) | [5.0](/filings/0001443669-26-000035.md) | [8.8](/filings/0001443669-25-000013.md) | [6.8 d](/filings/0001443669-26-000010.md) | [9.8](/filings/0001443669-26-000025.md) | [11.4](/filings/0001443669-26-000035.md) | | Income tax | $m | [2.8](/filings/0001628280-24-046196.md) | [2.9 d](/filings/0001443669-26-000010.md) | [2.5](/filings/0001628280-25-021822.md) | [2.8](/filings/0001628280-25-037024.md) | [2.7](/filings/0001443669-25-000013.md) | [0.1 d](/filings/0001443669-26-000010.md) | [2.4](/filings/0001443669-26-000025.md) | [2.2](/filings/0001443669-26-000035.md) | [3.0](/filings/0001443669-25-000013.md) | [2.2 d](/filings/0001443669-26-000010.md) | [3.2](/filings/0001443669-26-000025.md) | [3.5](/filings/0001443669-26-000035.md) | | Net income | $m | [8.0](/filings/0001628280-24-046196.md) | [7.0 d](/filings/0001443669-26-000010.md) | [5.3](/filings/0001443669-25-000013.md) | [4.5](/filings/0001443669-25-000013.md) | [7.2](/filings/0001443669-25-000013.md) | [(0.4) d](/filings/0001443669-26-000010.md) | [3.6](/filings/0001443669-26-000035.md) | [4.4](/filings/0001443669-26-000035.md) | [7.2](/filings/0001443669-25-000013.md) | [6.0 d](/filings/0001443669-26-000010.md) | [8.1](/filings/0001443669-26-000035.md) | [9.2](/filings/0001443669-26-000035.md) | | Diluted EPS | $ per share | [0.31](/filings/0001628280-24-046196.md) | not reported | [0.20](/filings/0001628280-25-021822.md) | [0.18](/filings/0001628280-25-037024.md) | [0.29](/filings/0001443669-25-000013.md) | not reported | [0.15](/filings/0001443669-26-000025.md) | [0.18](/filings/0001443669-26-000035.md) | [0.30](/filings/0001443669-25-000013.md) | not reported | [0.33](/filings/0001443669-26-000025.md) | [0.37](/filings/0001443669-26-000035.md) | | Basic EPS | $ per share | [0.31](/filings/0001628280-24-046196.md) | not reported | [0.21](/filings/0001628280-25-021822.md) | [0.18](/filings/0001628280-25-037024.md) | [0.29](/filings/0001443669-25-000013.md) | not reported | [0.15](/filings/0001443669-26-000025.md) | [0.19](/filings/0001443669-26-000035.md) | [0.30](/filings/0001443669-25-000013.md) | not reported | [0.34](/filings/0001443669-26-000025.md) | [0.38](/filings/0001443669-26-000035.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [83.5](/filings/0001628280-23-036667.md) | [83.8](/filings/0001628280-25-007052.md) | [92.8](/filings/0001628280-24-020233.md) | [96.1](/filings/0001628280-24-034354.md) | [87.9](/filings/0001628280-24-046196.md) | [89.1](/filings/0001443669-26-000010.md) | [82.7](/filings/0001628280-25-021822.md) | [90.4](/filings/0001628280-25-037024.md) | [104](/filings/0001443669-25-000013.md) | [111](/filings/0001443669-26-000035.md) | [124](/filings/0001443669-26-000025.md) | [128](/filings/0001443669-26-000035.md) | | Current assets | $m | [205](/filings/0001628280-23-036667.md) | [201](/filings/0001628280-25-007052.md) | [210](/filings/0001628280-24-020233.md) | [208](/filings/0001628280-24-034354.md) | [193](/filings/0001628280-24-046196.md) | [195](/filings/0001443669-26-000010.md) | [194](/filings/0001628280-25-021822.md) | [206](/filings/0001628280-25-037024.md) | [226](/filings/0001443669-25-000013.md) | [234](/filings/0001443669-26-000035.md) | [249](/filings/0001443669-26-000025.md) | [266](/filings/0001443669-26-000035.md) | | Total assets | $m | [784](/filings/0001628280-23-036667.md) | [772](/filings/0001628280-25-007052.md) | [770](/filings/0001628280-24-020233.md) | [758](/filings/0001628280-24-034354.md) | [754](/filings/0001628280-24-046196.md) | [744](/filings/0001443669-26-000010.md) | [737](/filings/0001628280-25-021822.md) | [743](/filings/0001628280-25-037024.md) | [757](/filings/0001443669-25-000013.md) | [763](/filings/0001443669-26-000035.md) | [779](/filings/0001443669-26-000025.md) | [791](/filings/0001443669-26-000035.md) | | Current liabilities | $m | [74.6](/filings/0001628280-23-036667.md) | [49.7](/filings/0001628280-25-007052.md) | [58.4](/filings/0001628280-24-020233.md) | [50.9](/filings/0001628280-24-034354.md) | [53.8](/filings/0001628280-24-046196.md) | [53.3](/filings/0001443669-26-000010.md) | [62.1](/filings/0001628280-25-021822.md) | [62.2](/filings/0001628280-25-037024.md) | [69.7](/filings/0001443669-25-000013.md) | [67.0](/filings/0001443669-26-000035.md) | [70.7](/filings/0001443669-26-000025.md) | [73.2](/filings/0001443669-26-000035.md) | | Total liabilities | $m | [99.3](/filings/0001628280-23-036667.md) | [77.1](/filings/0001628280-25-007052.md) | [82.5](/filings/0001628280-24-020233.md) | [73.0](/filings/0001628280-24-034354.md) | [73.8](/filings/0001628280-24-046196.md) | [73.4](/filings/0001443669-26-000010.md) | [80.6](/filings/0001628280-25-021822.md) | [78.5](/filings/0001628280-25-037024.md) | [92.1](/filings/0001443669-25-000013.md) | [89.5](/filings/0001443669-26-000035.md) | [95.4](/filings/0001443669-26-000025.md) | [99.6](/filings/0001443669-26-000035.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [685](/filings/0001628280-24-046196.md) | [695](/filings/0001443669-26-000010.md) | [687](/filings/0001443669-25-000013.md) | [685](/filings/0001443669-25-000013.md) | [680](/filings/0001443669-25-000013.md) | [670](/filings/0001443669-26-000035.md) | [657](/filings/0001443669-26-000035.md) | [665](/filings/0001443669-26-000035.md) | [665](/filings/0001443669-25-000013.md) | [674](/filings/0001443669-26-000035.md) | [683](/filings/0001443669-26-000035.md) | [692](/filings/0001443669-26-000035.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [24.2 d](/filings/0001628280-24-046196.md) | [17.2 d](/filings/0001443669-26-000010.md) | [21.3](/filings/0001628280-25-021822.md) | [14.4 d](/filings/0001628280-25-037024.md) | [24.8 d](/filings/0001443669-25-000013.md) | [17.3 d](/filings/0001443669-26-000010.md) | [18.4](/filings/0001443669-26-000025.md) | [10.6 d](/filings/0001443669-26-000035.md) | [29.1 d](/filings/0001443669-25-000013.md) | [16.5 d](/filings/0001443669-26-000010.md) | [17.5](/filings/0001443669-26-000025.md) | [15.4 d](/filings/0001443669-26-000035.md) | | Capital expenditure | $m | [3.1 d](/filings/0001628280-24-046196.md) | [18.2 d](/filings/0001443669-26-000010.md) | [2.6](/filings/0001628280-25-021822.md) | [4.2 d](/filings/0001628280-25-037024.md) | [1.6 d](/filings/0001443669-25-000013.md) | [0.8 d](/filings/0001443669-26-000010.md) | [1.3](/filings/0001443669-26-000025.md) | [1.5 d](/filings/0001443669-26-000035.md) | [4.1 d](/filings/0001443669-25-000013.md) | [8.1 d](/filings/0001443669-26-000010.md) | [3.5](/filings/0001443669-26-000025.md) | [6.2 d](/filings/0001443669-26-000035.md) | | Share repurchases | $m | [9.0 d](/filings/0001628280-24-046196.md) | [4.9 d](/filings/0001443669-26-000010.md) | [16.0](/filings/0001628280-25-021822.md) | [10.9 d](/filings/0001628280-25-037024.md) | [19.0 d](/filings/0001443669-25-000013.md) | [14.3 d](/filings/0001443669-26-000010.md) | [20.9](/filings/0001443669-26-000025.md) | [3.1 d](/filings/0001443669-26-000035.md) | [12.8 d](/filings/0001443669-25-000013.md) | [6.2 d](/filings/0001443669-26-000010.md) | [0.0](/filings/0001443669-26-000025.md) | [5.0 d](/filings/0001443669-26-000035.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [27.5](/filings/0001628280-23-036667.md) | [26.6](/filings/0001628280-24-020233.md) | [26.2](/filings/0001628280-24-034354.md) | [26.0](/filings/0001628280-24-046196.md) | [25.8](/filings/0001628280-25-021822.md) | [25.4](/filings/0001628280-25-037024.md) | [25.0](/filings/0001443669-25-000013.md) | [24.4](/filings/0001443669-26-000025.md) | [24.1](/filings/0001443669-26-000035.md) | [24.2](/filings/0001443669-25-000013.md) | [24.3](/filings/0001443669-26-000025.md) | [24.4](/filings/0001443669-26-000035.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 23,921,897 at 2026-07-28, from the cover of the [10-Q filed 2026-07-31](/filings/0001443669-26-000035.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.